RudaCure, a company specializing in the development of treatments for sensory disorders, drew significant attention at a major international rheumatology conference.
According to RudaCure Inc. (CEO Yongho Kim), the company presented preclinical efficacy results of its osteoarthritis treatment candidate under development at the American College of Rheumatology (ACR) Annual Meeting, held in San Diego, USA from the 10th to the 15th, receiving considerable interest from attendees.
The compound discovered by RudaCure features a mechanism that selectively inhibits TRPV1 activation. In prior studies, it demonstrated TRPV1 inhibitory effects and reduced pain in chronic pain animal models. Notably, unlike existing TRPV1 antagonists, it did not cause abnormal hyperthermia.
In addition to the poster presentation, RudaCure was also invited to the BCRC (Basic & Clinical Research Conference) session—one of the key programs at ACR 2023—where the company's cumulative research findings were presented directly to the audience.
RudaCure CEO Yongho Kim stated, "By moving away from traditional drug development methods with low success rates in the pain field and leveraging computational science, we were able to rapidly identify lead compounds," adding, "In particular, having a diverse range of pain models allowed us to quickly and accurately address drug development and side effect challenges, which is a key advantage."
He further noted, "Based on these research results, we plan to expand the indications for various pain conditions," and "We are also pursuing the development of a drug that can suppress pain for several months with a single administration through formulation research."
Source: Pharmnews (http://www.pharmnews.com)
http://www.biospectator.com/view/news_view.php?varAtcId=20336